期刊文献+

糖尿病与骨质疏松的研究进展 被引量:16

Research progress of diabetes mellitus and osteoporosis
下载PDF
导出
摘要 糖尿病(尤其是2型糖尿病)和骨质疏松是老年常见病,患病率迅速增加。1型糖尿病患者由于不能达到峰值骨量而导致骨折风险增加;2型糖尿病患者与骨密度的关系复杂,其较高的骨折风险不能仅靠诊断骨质疏松的金标准骨密度值来解释。其病因尚未完全明确,发病机制错综复杂,以往认为其发病与慢性高血糖、激素、细胞因子等关系密切,最新研究表明氧化应激和炎症介质也参与了糖尿病性骨质疏松的发生发展。 Diabetes mellitus (particularly type 2) and osteoporosis are two very common disorders , and are both increas-ing in prevalence .Patients with type 1 diabetes mellitus may not reach potential peak bone mass , putting them at greater fracture risk.While in patients with type 2 diabetes, fracture risk is increased and is not explained by the bone mineral density measured by dual -energy X-ray absorptiometry , which is considered the gold standard predictor of fracture .The etiology is not yet completely clear and pathogenesis is perplexing .It is closely related to chronic hyperglycemia , hormone and cytokines .Recent research shows that oxidative stress and inflammation mediators are also involved in the development of diabetic osteoporosis.
作者 罗巧彦 徐勇
出处 《大连医科大学学报》 CAS 2014年第2期190-194,共5页 Journal of Dalian Medical University
关键词 糖尿病 骨质疏松 流行病学 发病机制 diabetes mellitus osteoporosis epidemiology pathogenesis
  • 相关文献

参考文献2

二级参考文献24

  • 1Boonen S;Orwoll E;Magaziner J.Once-yearly zoledronic acid in older men compared with women with recent hip fracture,2011(11).
  • 2J. A. Kanis,O. Johnell.Requirements for DXA for the management of osteoporosis in Europe[J]. Osteoporosis International . 2005 (3)
  • 3NB Watts.What is osteopenia, and what should be done about it?. Cleveland Clinic Journal of Medicine . 2006
  • 4Schousboe,JT,Nyman,JA,Kane,RL,Ensrud,KE.Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Annals of Internal Medicine . 2005
  • 5Meadows ES,Klein R,Rousculp MD,et al.Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. BMC Womens Health . 2007
  • 6Black. The New England Journal of Medicine . 2007
  • 7Saag K,Lindsay R,Knegnma A,et al.A single zoredronic acidinfusion reduces bone resorption markers more rapidly thanweekly oral alendrenate in postmenopausal women with low bonemineral density. Bone . 2007
  • 8Reclast (zoledronic acid) injection[prescribing information]. . 2007
  • 9Bonnick SL,Shulman L.Monitoring osteoporosis therapy:bone mineral density,bone turnover markers,or both. The American Journal of The Medical Sciences . 2006
  • 10Reid IR,Brown JP,Burckhardt P,et al.Intravenous zoledronic acid in postmenopausal women with low bone mineral density. New England Journal of Medicine, The . 2002

共引文献37

同被引文献210

引证文献16

二级引证文献73

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部